Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials.

导出 LinkOut

翻译打印收藏纠错

作者： Szabolcs,Kiss ^[1] ; Noémi,Gede ^[2] ; Péter,Hegyi ^[3] ; Bettina,Nagy ^[2] ; Rita,Deák ^[2] ; Fanni,Dembrovszky ^[2] ; Stefania,Bunduc ^[4] ; Bálint,Erőss ^[2] ; Tamás,Leiner ^[5] ; Zsolt,Szakács ^[6] ; Hussain,Alizadeh ^[7]

作者单位： Doctoral School of Clinical Medicine, University of Szeged, Korányi fasor 8-10, Szeged, 6720, Hungary. ^[1] Institute for Translational Medicine, Medical School, University of Pécs, Szigeti Street 12, 2nd Floor, Pécs, 7624, Hungary. ^[2] Centre for Translational Medicine, Semmelweis University, Üllői Street 26, Budapest, 1085, Hungary. ^[3] Doctoral School, Carol Davila University of Medicine and Pharmacy, Bulevardul Eroii Sanitari 8, 050474, Bucureşti, Romania. ^[4] North West Anglia NHS Foundation Trust, Parkway Hinchingbrooke, Huntingdon, PE29 6NT, UK. ^[5] Division of Haematology, First Department of Medicine, Medical School, University of Pécs, Ifjúság Street 13, Pécs, 7624, Hungary. ^[6] Division of Haematology, First Department of Medicine, Medical School, University of Pécs, Ifjúság Street 13, Pécs, 7624, Hungary. alizadeh.hussain@pte.hu. ^[7]